Polyrizon Ltd.

Polyrizon Ltd., a clinical-stage biotech company developing nasal hydrogel technologies, reported a net loss of $3.3 million for FY 2025, up 116% from $1.5 million in FY 2024, driven by ramped-up R&D post-IPO. Operating loss widened to $6.2 million from $1.3 million YoY, with R&D expenses surging 299% to $2.1 million amid GMP batch production and usability studies for NASARIX™. G&A expenses rose 436% to $4.1 million, reflecting public company costs and a $0.5 million business email compromise loss. Financial income of $2.9 million, mainly from warrant revaluations, partially offset losses. Balance sheet strengthened with $21.4 million total assets, including $1.3 million cash and $16.2 million deposits; equity at $21.0 million. Cash burn from operations was $4.5 million, funded by $19.8 million financing inflows from PIPE ($15.1M) and IPO ($4.7M), netting a $1.2 million cash decline. No revenue generated as a development-stage firm. Management states cash suffices through March 2030, supporting NASARIX™ pivotal trials in Q3 2026 and PL-16 feasibility in Q3 2027, positioning for 510(k) clearance.

Key Takeaways